Symbol | Exchange | Currency |
|---|
This move is a reversal from the day prior, which saw price move down.The post Sarepta Therapeutics Inc (SRPT): Price Now Near $68.81; Daily Chart Shows Downtrend on 20 Day Basis...
The moving averages on the daily timeframe suggest a bearishness in price, as the 20, 50, 100 and 200 are all in a bearish alignment -- meaning the shorter duration moving...
Mizuho Securities analyst Difei Yang maintained a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) on Wednesday, setting a price target of $160, which is approximately 130.95%...
The biotech sector continues to be in focus with pipeline and regulatory updates.Recap of the Week’s Most Important Stories: Biogen’s Gene Therapy Studies Disappoint:...
Shares of Sarepta Therapeutics (NASDAQ:SRPT) SRPT closed 8.4% higher on Tuesday, and were up as much as 12% in earlier in the trading session after it announced positive data for...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Buy | Sell | Strong Sell | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Strong Sell | Strong Sell |
| Summary | Buy | Strong Buy | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,680.70 | 2,684.70 | 2,646.00 | +20.4 | +0.77% | 1.52M | NASDAQ | |||
| 372.46 | 374.44 | 368.22 | +2.67 | +0.72% | 14.81M | NASDAQ | |||
| 191.76 | 198.57 | 190.88 | -14.77 | -7.15% | 54.19M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 43.17 | 44.88 | 41.93 | -0.82 | -1.86% | 54.31M | NYSE | |||
| 192.94 | 194.42 | 189.14 | -2.64 | -1.35% | 20.24M | NASDAQ | |||
| 183.94 | 186.04 | 178.76 | +3.58 | +1.98% | 1.25M | NYSE | |||
| 2,792.90 | 2,794.30 | 2,753.00 | +36.6 | +1.33% | 1.15M | NASDAQ | |||
| 40.29 | 40.85 | 37.57 | +3.30 | +8.92% | 97.43M | NYSE | |||
| 21.31 | 21.63 | 20.76 | +0.50 | +2.40% | 5.59M | NYSE | |||
| 192.62 | 193.95 | 191.20 | +0.44 | +0.23% | 1.02M | NASDAQ | |||
| 251.15 | 252.44 | 248.52 | +2.26 | +0.91% | 368.34K | NYSE | |||
| 0.5936 | 0.00 | 0.00 | +0.0035 | +0.59% | 1.02M | NYSE | |||
| 6.18 | 6.28 | 6.11 | +0.060 | +0.98% | 9.89M | NYSE | |||
| 61.12 | 61.88 | 59.66 | +1.17 | +1.95% | 1.32M | NYSE |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
